Cambridge Investment Research Advisors’s Anixa Biosciences ANIX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-41,104	Closed	-$129K	–	3471
2024 Q3	$129K	Buy	41,104 +104	+0.3%	+$320	﹤0.01%	3228
2024 Q2	$91K	Hold	41,000	–	–	﹤0.01%	3163
2024 Q1	$128K	Buy	41,000 +1,000	+3%	+$3.99K	﹤0.01%	3116
2023 Q4	$155K	Sell	40,000 -100	-0.2%	-$337	﹤0.01%	2962
2023 Q3	$131K	Hold	40,100	–	–	﹤0.01%	2921
2023 Q2	$128K	Hold	40,100	–	–	﹤0.01%	2963
2023 Q1	$172K	Hold	40,100	–	–	﹤0.01%	2869
2022 Q4	$170K	Buy	40,100 +25,100	+167%	+$121K	﹤0.01%	2801
2022 Q3	$74K	Buy	+15,000	New	+$60.8K	﹤0.01%	2898

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MWM

Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Cambridge Investment Research Advisors's ANIX Position: Q4 2024 in Review

Cambridge Investment Research Advisors sold out of Anixa Biosciences (ANIX) in Q4 2024, closing a stake of 41,104 shares — an estimated $129K sold.

Cambridge Investment Research Advisors first reported a position in ANIX in Q3 2022 and held it in 9 quarters. The position peaked at $172K in Q1 2023. 57 funds tracked by Wall St. Rank hold ANIX as of Q4 2024.

Cambridge Investment Research Advisors reported no remaining Anixa Biosciences position as of Q4 2024 after selling out during the quarter.
Cambridge Investment Research Advisors sold 41,104 Anixa Biosciences shares in Q4 2024, an estimated $129K.
Cambridge Investment Research Advisors first reported a position in Anixa Biosciences in Q3 2022 and held it in 9 quarters.
Cambridge Investment Research Advisors's Anixa Biosciences position peaked at $172K in Q1 2023.
57 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.